reaction mixture, ranging from 0.1 to 1.2 mmol/L, with color intensity at 520 nm up to an absorbance of 0.11. The analytical recovery of added oxalate (20 and 40 nmol/sample) was 97 Ϯ 2%. The within-and betweenday CV for urinary oxalate values (n ϭ 5) were Ͻ3.0% and Ͻ6.0%, respectively. The oxalate values in 24-h urine from apparently healthy individuals (male, n ϭ 100) were 89 -258 mol/day, with a mean of 185.5. To evaluate the accuracy of the method, we determined the oxalate values in urine samples (n ϭ 20) by the Sigma kit method (x) with modification (11) and by the present method (y). The modified Sigma kit method included the precipitation of urinary oxalate by CaCl 2 and ethanol and its redissolution in 0.1 mol/L HCl for removal of ion interference (7) , treatment with activated charcoal for removal of ascorbate interference, and measurement of H 2 O 2 generated from urinary oxalate by barley oxalate oxidase in sodium succinate buffer, pH 5.0, by a color reaction using 3-methyl-3-benzothiozolinone and 3-(dimethylamine)benzoic acid and horseradish peroxidase as chromogen (11) . The oxalate values obtained by the two methods showed a good correlation (r ϭ 0.9632) with the following regression equation: y ϭ 0.839x Ϫ 0.0025, for a mean value of 27 Ϯ 44 mg/L. To test the possible interference by various salts and organic substances found in urine, the following compounds were added in the reaction mixture each at two final concentrations of 0.5 and 1.0 mmol/L: NaCl, KCl, CuSO 4 , FeSO 4 , MgSO 4 , MnCl 2 , PbCl 2 , CdCl 2 , CH 3 COOK, CH 3 COONa, NaNO 3 , Na 2 HPO 4 , Na 2 CO 3 , urea, glycine, pyruvate, glutamate, citrate, glucose, fructose, creatinine, glycollate, glyoxylate, NADH, and ascorbate. Of these compounds, only ascorbate and NADH caused 91% and 80% inhibition of the color reaction, respectively, at 0.5 mmol/L concentration, which increased to 100% at 1.0 mmol/L concentration in both the cases. Other compounds had practically no effect. NaCl had no effect, even at higher concentrations such as 50, 100, and 200 mmol/L. However, many of these substances may be present in urine at even higher concentrations in various disease states and, therefore, may need to be tested more thoroughly.
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The Mutation G 20210 3 A in the Prothrombin Gene Is a Strong Risk Factor for Pulmonary Embolism
To the Editor: It has been reported recently by Poort et al. (1) that the mutation G 20210 3 A in the 3Ј-untranslated region of the prothrombin gene is associated with increased plasma prothrombin concentrations and venous thrombosis. The G 20210 3 A mutation was found in 18% of 28 selected patients with a personal and family history of venous thrombosis as well as in 6.2% of 471 unselected patients with a first episode of deep venous thrombosis. On the other hand, only 2.3% of 474 healthy control subjects carried the mutation. It was concluded that the G 20210 3 A mutation in the prothrombin gene is a risk factor for venous thrombosis (1), which was most recently confirmed by other groups (2) (3) (4) .
Against this background, we addressed the question of whether pulmonary embolism as a complicated form of venous thrombosis is also associated with the G 20210 3 A transition in the 3Ј-untranslated region of the prothrombin gene. Therefore, we analyzed the blood samples of 27 unselected consecutive patients (11 males and 16 females; 14 -78 y of age; mean age, 53 y) with pulmonary embolism for the presence of the mutation. Pulmonary embolism was related to deep venous thrombosis of the lower limbs in 10 of 27 patients (37%). For 20 patients (74%), pulmonary embolism with or without combination of deep venous thrombosis was the first event of thromboembolism, whereas the remaining 7 patients (26%) had thromboembolic events in the past. Blood samples from 245 healthy blood donors (ages 20 -67 y; mean age, 45 y) were analyzed as controls. Pulmonary embolism was diagnosed by ventilationperfusion lung scanning (n ϭ 19), repeated perfusion lung scanning (n ϭ 3), or clinically in combination with echocardiography and electrocardiography if unequivocal (n ϭ 2). Questionable cases were verified by pulmonary artery angiography (n ϭ Clinical Chemistry 44, No. 6, 1998
3). Genomic DNA was prepared from peripheral blood leukocytes as described previously (5) . Amplification of genomic DNA was performed by PCR as described (1) . The G3 A substitution at nucleotide position 20210 was detected by allele-specific restriction digestion by using HindIII (1) .
Among the 27 patients, 4 (14.8%) were heterozygous for the G 20210 3 A mutation in the prothrombin gene and 1 patient (3.7%) was homozygous, whereas 22 patients (81.5%) did not carry the mutation (Table  1) . Among the 245 healthy control persons, 239 subjects (97.6%) did not carry the G 20210 3 A mutation, whereas 6 persons (2.4%) were heterozygous, and none was homozygous for the mutation ( Table 1) . The difference of frequencies between the group of patients (18.5%) and the controls (2.4%) was statistically significant (P Ͻ0.005, Fisher's Exact test; integral part of GraphPad Prism TM , Ver. 2.0, Graph-Pad Software, Inc.). The mutation G 20210 3 A in the prothrombin gene increased the risk for pulmonary embolism approximately ninefold (odds ratio, 9.1; 95% confidence interval, 2.6 -32.1) compared with noncarriers of the mutation (Table 1) .
Among the 27 patients, 3 (11.1%) were heterozygous or homozygous for factor V Leiden mutation, and 2 (7.4%) had a protein C deficiency. One subject (3.7%) exhibited protein S deficiency, whereas no patient had antithrombin III deficiency. The patient homozygous for the G 20210 3 A mutation in the prothrombin gene was also heterozygous for factor V Leiden mutation. However, no further coincidence existed between carriers of the G 20210 3 A mutation in the prothrombin gene and the abovedescribed risk factors for thrombophilia. It has been reported recently that the prevalence of factor V Leiden mutation is high in patients with pulmonary embolism associated with deep venous thrombosis, whereas it is similar to that of controls in subjects with isolated pulmonary embolism (6) . In our study, 2 patients of 17 with isolated pulmonary embolism (12%) carry the factor V Leiden mutation compared with 1 patient of 10 with pulmonary embolism related to deep venous thrombosis (10%), which was not a significant difference. Furthermore, we found the G 20210 3 A mutation in the prothrombin gene in 3 of 10 patients (30%) with pulmonary embolism associated with deep venous thrombosis and in 2 of 17 patients (12%) with isolated pulmonary embolism. Because of the small number of patients in the subgroups, these differences were not significant (P ϭ 0.4).
Although our study is based on a relatively small group of patients, the odds ratio of 9.1 (95% CI, 2.6 -32.1) suggests that the mutation G 20210 3 A in the prothrombin gene is a strong, independent risk factor for pulmonary embolism.
Karl Heinrich Reuner* Andreas Ruf Frank Litfin Heinrich Patscheke Institute for Medical Laboratory Diagnostics Klinikum Karlsruhe
Moltkestrasse 90 D-76133 Karlsruhe, Germany * Author for correspondence. Fax 0721/ 974-1769.
The Value of Free Enterprise
To the Editor: Dr. Relman, in his AACC Lectureship Award Address, derides the free enterprise system's role in healthcare because it distorts the interests of the caregivers. Yet Dr. Relman receives much of his public reputation as the former Editor of The New England Journal of Medicine, a journal that has profited from the rich support it receives from its advertisers. We accept this commercial support without criticizing the integrity of its recipient. We believe The New England Journal of Medicine has not compromised its principles.
The field of laboratory medicine provides tremendous benefit to society because of the contributions of individuals and organizations who have benefited from the free enterprise system. The contributions of Arnold Beckman, Jack Whitehead, 
